It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Posterior chamber phakic intraocular lens (pIOL) implantation is a common option for correcting moderate-to-high ocular refractive defects. Because this pIOL is implanted on ciliary sulcus, the distance between the back surface of the pIOL and the anterior surface of the crystalline lens, that it is known as vault, should be measured in different conditions to ensure the technique’s safety. Cyclopentolate is a drug that dilates the pupil and relaxes accommodation (cycloplegia). It is often used for different ocular examinations and for other medical purposes. However, there is no evidence of the effect of this drug on vault. This study quantified central vault changes associated with cyclopentolate instillation. We measured the vault under normal conditions (pre-cycloplegic instillation) and after instilling cyclopentolate on 39 eyes of 39 patients with implanted pIOL. Our results suggest that cyclopentolate instillation may induce changes to vault in eyes with implanted pIOL. These changes seem safe and are mainly associated with vault under normal conditions, but also with anterior chamber depth, pupillary diameter and pIOL size.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Clínica Novovisión, Department of Ophthalmology, Murcia, Spain; University of Sevilla, Departament of Condensed Matter Physics, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
2 General University Hospital Morales Meseguer, Departament of Ophthalmology, Murcia, Spain (GRID:grid.411101.4) (ISNI:0000 0004 1765 5898); University of Murcia, Department of Ophthalmology and Optometry, Murcia, Spain (GRID:grid.10586.3a) (ISNI:0000 0001 2287 8496)
3 Clínica Novovisión, Department of Ophthalmology, Murcia, Spain (GRID:grid.10586.3a); General University Hospital Morales Meseguer, Departament of Ophthalmology, Murcia, Spain (GRID:grid.411101.4) (ISNI:0000 0004 1765 5898)
4 University of Minho, Clinical & Experimental Optometry Research Lab, Center of Physics, Braga, Portugal (GRID:grid.10328.38) (ISNI:0000 0001 2159 175X)
5 Clínica Novovisión, Department of Ophthalmology, Murcia, Spain (GRID:grid.10328.38); European University of Madrid, Faculty of Biomedicine and Health, Madrid, Spain (GRID:grid.119375.8) (ISNI:0000000121738416)
6 Clínica Novovisión, Department of Ophthalmology, Murcia, Spain (GRID:grid.10328.38); University of Murcia, Department of Ophthalmology and Optometry, Murcia, Spain (GRID:grid.10586.3a) (ISNI:0000 0001 2287 8496)